

Ghana Support for Meningitis A Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ghana 2. Grant number: 1619-GHA-28a-X; 16-GHA-08j-Y 3. Date of Decision Letter: 19 March 2019 4. Date of the Partnership Framework Agreement: 11 July 2014 5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Routine 6. Vaccine type: Meningitis A 7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED 8. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) Programme 2016-2018 2019 Total ² Programme US\$1,735,548 ³ US\$226,000 US\$1,961,548 10. Vaccine introduction grant (in US\$) US\$1,961,548 2019 Total ² Programme US\$1,735,548 ³ US\$226,000 US\$1,961,548 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year 2016-2018 2019 2019 423,000 doses 423,000 423,000 20\$226,000 12\$226,000 12\$226,000 12\$226,000					
3. Date of Decision Letter: 19 March 2019 4. Date of the Partnership Framework Agreement: 11 July 2014 5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Routine 6. Vaccine type: Meningitis A 7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED 8. Programme duration ¹ : 2016 -2019 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) 2016-2018 2019 Total ² Programme US\$1,735,548 ³ US\$ 914,500 disbursed on 3 June 2016 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 Type of supplies to be purchased with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines with Gavi funds in each year 423,000 Number of Meningitis A vaccines 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000	1. Country: Gha	na			
4. Date of the Partnership Framework Agreement: 11 July 2014 5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Routine 6. Vaccine type: Meningitis A 7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED 8. Programme duration ¹ : 2016 -2019 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) Programme Budget (US\$) 2016-2018 2019 Total ² Programme UUS\$1,735,548 ³ US\$226,000 US\$1,961,548 US\$ 914,500 disbursed on 3 June 2016 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines with Gavi funds in each year 423,000 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing	2. Grant number	r: 1619-GHA-28a-X	16-GHA-08j-Y		
5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Routine 6. Vaccine type: Meningitis A 7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED 8. Programme duration ¹ : 2016 - 2019 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) 2016-2018 2019 Total ² Programme Budget (US\$) US\$1,735,548 ³ US\$226,000 US\$ 914,500 disbursed on 3 June 2016 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines 423,000 423,000 doses Annual Amounts (US\$) US\$1,735,548 ⁶ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing	3. Date of Decis	ion Letter: 19 March	n 2019		
6. Vaccine type: Meningitis A 7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED 8. Programme duration ¹ : 2016 -2019 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) Programme Budget (US\$) US\$1,735,548 ³ US\$226,000 US\$1,961,548 Io. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines 423,000 423,000 doses 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing	4. Date of the Pa	artnership Framewo	ork Agreement: 11	1 July 2014	
7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED 8. Programme duration ¹ : 2016 -2019 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) 2016-2018 2019 Programme US\$1,735,548 ³ US\$1,735,548 ³ US\$226,000 US\$ 914,500 disbursed on 3 June 2016 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines 423,000 423,000 doses US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing 10	5. Programme ti	tle: New Vaccine Su	ipport (NVS), Meni	ngitis A Preventive F	Routine
type A, 10 dose(s) per vial, LYOPHILISED 8. Programme duration ¹ : 2016 -2019 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) 2016-2018 2019 Total ² Programme 2016-2018 2019 Total ² Programme US\$1,735,548 ³ US\$226,000 US\$1,961,548 Budget (US\$) US\$1,735,548 ³ US\$226,000 US\$1,961,548 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year 423,000 423,000 Mumber of Meningitis A vaccines 423,000 423,000 doses US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing	6. Vaccine type:	Meningitis A			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) 2016-2018 2019 Programme Budget (US\$) US\$1,735,548 ³ US\$226,000 US\$1,961,548 Budget (US\$) US\$1,735,548 ³ 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year 423,000 423,000 Number of Meningitis A vaccines 423,000 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing 10. US\$1,735,548 ⁵ US\$226,000				of vaccine: Meningo	ococcal
Framework Agreement, if applicable) 2016-2018 2019 Total ² Programme US\$1,735,548 ³ US\$226,000 US\$1,961,548 Budget (US\$) US\$1,735,548 ³ US\$226,000 US\$1,961,548 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ 2016-2018 2019 Type of supplies to be purchased year 2016-2018 2019 Number of Meningitis A vaccines doses 423,000 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing 10	8. Programme d	uration ¹ : 2016 -201	9		
Programme Budget (US\$) US\$1,735,548 ³ US\$226,000 US\$1,961,548 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ 2016-2018 2019 Type of supplies to be purchased with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines doses 423,000 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing 10.548				ns of the Partnership	
Budget (US\$) 10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased with Gavi funds in each year 2016-2018 Number of Meningitis A vaccines doses 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing		2016-2018	2019	Total ²	
US\$ 914,500 disbursed on 3 June 2016 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ Type of supplies to be purchased 2016-2018 2019 with Gavi funds in each year Number of Meningitis A vaccines 423,000 doses 423,000 Innual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing		US\$1,735,548 ³	US\$226,000	US\$1,961,548	
Agreement, if applicable) ⁴ Type of supplies to be purchased with Gavi funds in each year 2016-2018 2019 Number of Meningitis A vaccines doses 423,000 423,000 Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing			-		
with Gavi funds in each year 423,000 Number of Meningitis A vaccines 423,000 doses 1000000000000000000000000000000000000		```	ject to the terms of	f the Partnership Fra	mework
doses US\$1,735,548 ⁵ Annual Amounts (US\$) US\$1,735,548 ⁵ 12. Procurement agency: UNICEF. The Country shall release its co-financing			2016-2018		2019
Annual Amounts (US\$) US\$1,735,548 ⁵ US\$226,000 12. Procurement agency: UNICEF. The Country shall release its co-financing					423,000
12. Procurement agency: UNICEF. The Country shall release its co-financing					
	Annual Amounts (US\$)		US\$1,735,548 ⁵	U	S\$226,000
payments each year to UNICEF.			he Country shall re	elease its co-financin	g
	payments eac	h year to UNICEF.			
13. Self-procurement: Not applicable	13. Self-procuren	nent: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



14. Co-financing obligations: Reference code: 1619-GHA-28a-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in	2019
each year	
Number of vaccine doses	180,000
Number of AD syringes	85,700
Number of re-constitution syringes	19,800
Number of safety boxes	1,175
Value of vaccine doses (US\$)	US\$93,516
Total co-financing payments (US\$) (including freight)	US\$101,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and information	Due dates
 To prepare for the annual procurement of vaccines, Country shall submit the following information each year: vaccine stock levels including buffer stock, by end of March; 	31 March 2019
 number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and	To be agreed with Secretariat

Signed by,

Flind H. Ehatel

On behalf of Gavi Hind Khatib-Othman Managing Director, Country Programmes 19 March 2019